XTL Biopharmaceuticals targets Psyga Bio deal close by June 30 under Nasdaq exception

• XTL Biopharmaceuticals agreed to acquire all issued and outstanding share capital of Psyga Bio on a fully diluted basis, subject to closing conditions.
• Transaction timeline targets closing no later than June 29, 2026, following shareholder approval.
• Deal financing includes a commitment of up to USD 1.5 million through a private placement to be completed at closing.
• Nasdaq granted an exception for continued listing that requires completion of Psyga transaction by June 30, 2026, alongside compliance with continued listing standards.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. XTL Biopharmaceuticals Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-053067), on May 07, 2026, and is solely responsible for the information contained therein.